Introduction
============

Multiple myeloma (MM) is a hematologic disease characterized by the proliferation of malignant plasma cells, causing disease-related symptoms such as anemia, hypercalcemia, renal and bone disease. The age-standardized incidence rate is 4.5 per 100,000.^[@b1-1041026]^ Incidence increases with age and two-thirds of the patients diagnosed with MM are over 65 years of age.^[@b2-1041026]^ The treatment armamentarium has been greatly increased in the last decade, with novel proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies now being incorporated in first-line treatment regimens, which have considerably improved progression-free survival (PFS) and overall survival (OS) of MM. Given the median age of 70 years at diagnosis, the majority of newly diagnosed (ND) MM patients are not transplant eligible (NTE) for stem cell transplant (SCT). Current standards of care for NTE NDMM patients are bortezomib-melphalan-prednisone (VMP), lenalidomide-dexamethasone (Rd), and in the USA bortezomib-Rd (Vrd),^[@b3-1041026]^ supported by randomized phase III trials.^[@b4-1041026]--[@b6-1041026]^ Recently, better PFS was demonstrated for daratumumab-VMP (DaraVMP) compared to VMP.^[@b7-1041026]^

Although randomized clinical trials (RCTs) remain the gold standard to define standards of care, we predict that in the current treatment landscape the role of network meta-analysis (NMA) will become increasingly important. Firstly, today there is more than one standard of care, but a randomized study between two registered standards of care is highly unlikely to be performed because of the reluctance of pharmaceutical industries to support such studies.^[@b8-1041026]^ Therefore, head-to-head comparisons of VMP *versus* Rd or VRd *versus* VMP are not likely to be initiated.^[@b9-1041026]^ NMA can help to discriminate between efficacy of non-head-to-head compared regimens. Secondly, with the increase in the number of treatment modalities, the number of smaller randomized Phase II studies is expected to increase at the cost of Phase III RCTs. NMA provides more solid estimates of treatment effects by combining RCTs that provide direct and indirect evidence for effectiveness and allows competing treatments to be ranked.^[@b10-1041026]^ Thirdly, with the high number of studies currently enrolling patients, standard of care arms are expected to change within short time frames.^[@b8-1041026]^ This hampers the development of classical phase III trials, as at the end of the study it might appear that the standard arm of the study no longer reflects the reality in the clinic. Finally, the heterogeneous biological characteristics of MM and the clonal evolution of the disease will lead to studies with a smaller sample size that will not allow for randomization, increasing the need for indirect comparisons.

There are currently two systematic literature reviews (SLRs) and NMAs available for first-line NTE NDMM treatments.^[@b11-1041026],[@b12-1041026]^ Due to the timing of their searches and selection criteria, these reviews did not, however, include all currently available treatments (e.g. VRd, VMPT-VT, DaraVMP) and RCT evidence (e.g. HOVON87 comparing MPT-T and MPR-R^[@b13-1041026]^). To support evidence-based decision making in clinical practice, we performed an SLR and an NMA synthesizing all direct and indirect evidence from phase III RCTs that is currently available and compared the outcome of all treatment options for NTE NDMM patients.

Methods
=======

Systematic literature review
----------------------------

An SLR was conducted in the databases EMBASE®, MED-LINE®, MEDLINE®-in-Process and the Cochrane Central Register of Controlled Trials for the period January 1, 1999 to March 1, 2016 to identify relevant studies (*Online Supplementary Appendix 1*). Studies were included if they described a Phase III RCT among newly diagnosed adult patients with MM. Furthermore, one of the pre-specified treatments (*Online Supplementary Appendix 2*) had to be part of the regimens of the RCT. After removing duplicates, citations were first screened on the basis of title and abstract and then screened on the contents of their full text. Citations were excluded due to the following reasons: not in English, review, study phase, intervention, disease, study design, meta-analysis, patient population, economic outcomes, meta-analysis, and other. (For a detailed description of the exclusion categories see *Online Supplementary Appendix 2*). To incorporate the latest clinical developments, the publication of the pre-specified interim analysis of the phase III ALCYONE RCT comparing DaraVMP to VMP^[@b7-1041026]^ was added as additional record.

Data extraction
---------------

Data were extracted on trial details (i.e. publication source, trial ID, trial number, research, and comparator treatment(s), number of patients, median age, and primary outcome, and follow up) and efficacy outcomes. Efficacy outcomes included PFS and OS. For OS we obtained median survival. For PFS we obtained the median survival, 95% confidence interval (CI) and hazard ratio (HR) and 95%CI of the HR. In cases in which HRs and/or 95%CI for PFS were not reported, we estimated the missing data with the available Kaplan-Meier curves using the methods described by Tierney *et al*.^[@b14-1041026]^ In cases in which multiple sources reported on the same trial, the most recently published PFS data were extracted. Risk of bias in randomized trials was assessed using the Cochrane Collaboration tool^[@b15-1041026]^ (*Online Supplementary Appendix 3*).

Network meta-analysis
---------------------

A network was made from the identified treatment options in the SLR. It includes the HRs for PFS from the trials for treatments that were compared head-to-head. A comparison between all treatments can be made based on a common comparator (i.e. reference treatment). The choice of the reference treatment does not influence the outcomes of the study and final results can be presented relative to all included treatments. The oldest treatment (i.e. dexamethasone) was selected as a reference treatment from which the relative effectiveness of all treatments was estimated. We performed a similar analysis with MPT as reference treatment, given that this regimen was used as (comparator) treatment in several RCTs. Treatments were sorted based on their *P*-score. This *P*-score measures the average proportion of treatments worse than the respective treatment where 1 means theoretically the best and 0 means the worst.^[@b16-1041026]^

To conduct an NMA for 2- and multi-arm studies, we used the netmeta package v.0.9-7 in R version 3.3.1 (*Online Supplementary Appendix 4*). We ran a random effects model assuming that the included studies represent a random sample of effect sizes that could have been observed and that the effect can best be estimated by the mean of all available studies. A random effects model was deemed appropriate since there were multiple trials available for some comparisons (e.g. MPT with MP) and sampling error was not considered to be the most plausible explanation for the observed variation. With a random effects model we allow for differences in the patient population and implementations of interventions.^[@b17-1041026]^ The netmeta package uses a frequentist approach based on the graph-theoretical methods routinely applied in electrical networks.^[@b18-1041026],[@b19-1041026]^ In contrast to the Bayesian approach that produces credible intervals, analysis based on the frequentist approach produces 95%CIs and, as all CIs, these should be interpreted as follows: 95% of the produced CIs would contain the true value if the analysis were repeated many times.^[@b20-1041026]^

Face-validity of the NMA results was checked by comparing the computed HRs by the NMA with the HRs reported in the publications of the trials. To validate our outcomes to a previously reported NMA,^[@b12-1041026]^ we performed a scenario analysis with different treatment groups (separating MPT and MPT-T) and a scenario with a limited number of studies. In the third scenario analysis, we used a fixed effect model instead of a random effects model. Heterogeneity and inconsistency were assessed by decomposing the Q statistic^[@b21-1041026],[@b22-1041026]^ and quantified by the I^2^-statistic,^[@b23-1041026]^ which presents the percentage of the variability in effects due to heterogeneity rather than chance.^[@b24-1041026]^

Results
=======

Systematic literature review
----------------------------

[Figure 1](#f1-1041026){ref-type="fig"} presents the PRISMA flow diagram; the PRISMA checklist is presented in *Online Supplementary Appendix 3*. The SLR identified a total of 19,773 citations from the databases. One additional recent record was included (i.e. the ALCYONE trial^[@b7-1041026]^). After removing duplicates, 18,752 citations remained. Based on title and abstract, 17,741 citations were excluded for further analysis. The full texts of 1011 citations were reviewed and, based on this assessment, 944 citations were excluded. In the second full text review of the remaining 67 citations, 43 citations were excluded because these did not report the most recent results (e.g. extended follow-up results were available). After the entire assessment, 24 RCTs remained and were included for data extraction and the NMA. See [Figure 1](#f1-1041026){ref-type="fig"} for further details of the reasons for exclusion.

![PRISMA 2009 flow diagram: transplant not eligible multiple myeloma (TNEMM) Phase III randomized controlled trials (RCTs). n: number. From Moher *et al*. 2009.^[@b52-1041026]^](1041026.fig1){#f1-1041026}

These 24 RCTs included 21 treatment options: 1) Dexamethasone (D), 2) Dexamethasone-Interferon alpha (DI), 3) Melphalan 100 (M100), 4) Melphalan-Dexamethasone (MD), 5) Melphalan-Prednisone (MP), 6) Thalidomide-Dexamethasone (TD), 7) Cyclophosphamide-Thalidomide-Dexamethasone (CTD), 8) Cyclophosphamide-Thalidomide-Dexamethasone (attenuated) \[CTD(a)\], 9) Melphalan-Prednisone-Thalidomide/Melphalan-Prednisone-Thalidomide and Thalidomide maintenance (MPT/MPT-T), 10) Bortezomib-Dexamethasone (VD), 11) Bortezomib-Thalidomide-Dexamethasone (VTD), 12) Bortezomib-Melphalan-Prednisone (VMP), 13) Bortezomib-Thalidomide-Prednisone (VTP), 14) Bortezomib-Melphalan-Prednisone-Thalidomide and Bortezomib-Thalidomide (VMPT-VT), 15) Cyclophosphamide-Prednisone-Lenalidomide (CPR), 16) Lenalidomide-Dexamethasone (Rd), 17) 18 cycles Lenalidomide-Dexamethasone (Rd18), 18) Melphalan-Prednisone-Lenalidomide (MPR), 19) Melphalan-Prednisone-Lenalidomide and Lenalidomide maintenance (MPR-R), 20) Bortezomib-Lenalidomide-Dexamethasone (VRd), 21) Daratumumab-Bortezomib-Melphalan-Prednisone (DaraVMP).

Data extraction
---------------

[Table 1](#t1-1041026){ref-type="table"} provides the details, and extracted and calculated data of the included trials. Most trials (21 out of 24) investigated iMID-based regimens (thalidomide or lenalidomide). Since MP has been the standard treatment for decades,^[@b25-1041026]^ MP was the comparator in 12 trials. PFS was the primary end point for 13 trials. The median age of the patient population was reported by most trials and ranged from 64 to 79 years. While some trials included patients aged \<65 years, either because of choosing broader age limits or because of including patients who were not eligible for SCT independent of age, most trials only included patients aged ≥65 years. The IFM99-06^[@b26-1041026]^ and IFM01/01^[@b27-1041026]^ only focused on patients aged ≥70 and ≥75, respectively.

###### 

Data extraction of the included trials.

![](1041026.tab1)

Network meta-analysis network
-----------------------------

All identified RCTs (n=24) and treatments (n=21) were incorporated within one network ([Figure 2](#f2-1041026){ref-type="fig"}). We combined MPT and MPT-T. The duration of induction therapy with thalidomide varied leading to a clear overlap in planned thalidomide use between protocols with and without maintenance, preventing a clear discrimination between MPT with and without thalidomide maintenance.

![Network of the studies included in the network meta-analysis (NMA). White boxes represent treatments and reference numbers using the following abbreviations. 1) Dexamethasone (D); 2) Dexamethasone-Interferon alpha (DI); 3) Melphalan 100 (M100); 4) Melphalan-Dexamethasone (MD); 5) Melphalan-Prednisone (MP); 6) Thalidomide-Dexamethasone (TD); 7) Cyclophosphamide-Thalidomide-Dexamethasone (CTD); 8) Cyclophosphamide-Thalidomide-Dexamethasone (attenuated) \[CTD(a)\]; 9) Melphalan-Prednisone-Thalidomide / Melphalan-Prednisone-Thalidomide and Thalidomide maintenance (MPT/MPT-T); 10) Bortezomib-Dexamethasone (VD); 11) Bortezomib-Thalidomide-Dexamethasone (VTD); 12) Bortezomib-Melphalan-Prednisone (VMP); 13) VTP: Bortezomib-Thalidomide-Prednisone (VTP); 14) Bortezomib-Melphalan-Prednisone-Thalidomide and Bortezomib-Thalidomide (VMPT-VT); 15) Cyclophosphamide-Prednisone-Lenalidomide (CPR); 16) Lenalidomide-Dexamethasone (Rd); 17) 18 cycles Lenalidomide-Dexamethasone (Rd18); 18) Melphalan-Prednisone-Lenalidomide (MPR); 19) Melphalan-Prednisone-Lenalidomide and Lenalidomide maintenance (MPR-R); 20) Bortezomib-Lenalidomide-Dexamethasone (VRd); 21) Daratumumab-Bortezomib-Melphalan-Prednisone (DaraVMP). Black box represents the reference treatment in the network meta-analysis. Gray boxes include the trial reference and hazard ratio (HR) for progression-free survival on the top row(s). Bottom row shows HR according to the NMA. \*HR not statistically significant at 5%.](1041026.fig2){#f2-1041026}

[Figure 2](#f2-1041026){ref-type="fig"} presents the obtained HR(s) from the trial(s) and the HR obtained from the NMA for each of the connections (i.e. treatment comparisons) in our network. In order to validate our data, we compared the HR from treatments for which only direct evidence from a single RCT was available. The HR obtained from the NMA should be equal to the HR obtained from the RCT. The HR from the NMA was indeed similar to the HR from the trials for six comparisons^[@b5-1041026]--[@b7-1041026],[@b28-1041026]--[@b30-1041026]^ \[i.e. CTD(a) *vs*. MP, VMP *vs*. MP, DaraVMP *vs*. VMP, VRd *vs*. Rd, VMPT-VT *vs*. VMP and VMP *vs*. VTP\] (*Online Supplementary Appendix 5*). In addition, our network includes several treatments for which both direct and indirect evidence were available. *Online Supplementary Appendix 5* presents the HRs based on direct and indirect evidence and shows that none of the *P*-values for disagreement was lower than 0.05.

The percentage of the variability in effect estimates due to heterogeneity rather than sampling error (=I^2^) was 72% indicating substantial between-study heterogeneity (i.e. within the 50-90% range can be quantified as substantial heterogeneity^[@b24-1041026]^). We allowed for between-study heterogeneity by using the random effects model. Heterogeneity could be reduced by excluding some of the trials; however, because of a lack of valid reasons (e.g. patients' characteristics, treatment dosing or follow up) for excluding trials, we decided not to perform analyses of this kind.

Results *versus* dexamethasone
------------------------------

[Figure 3](#f3-1041026){ref-type="fig"} presents the HRs with the corresponding 95%CI for PFS and the *P*-score of the NMA in which dexamethasone was used as comparator for the remaining 20 "other treatment" options. HRs above 1 indicate that the "other treatment" is less effective than the comparator treatment, dexamethasone; HRs below 1 indicate that the "other treatment" is more effective than dexamethasone. All first-line NTE NDMM treatment options were better compared to the reference treatment dexamethasone (i.e. reducing the risk of progression or death compared to dexamethasone). HRs ranged between 0.19-0.90; however, not all treatments were statistically significantly different from dexamethasone, because of wide 95%CIs. DaraVMP and VMPT-VT were identified as the most effective treatment options as they had the highest and almost similar *P*-scores (i.e. a 96% and 93% certainty that this treatment is better than another treatment, averaged over all competing treatments) and most favorable relative treatment effects compared to dexamethasone (i.e. HR: 0.19, 95%CI: 0.08-0.45 and HR 0.22, 95%CI: 0.10-0.51 for DaraVMP and VMPT-VT, respectively). The HRs and 95%CIs for currently recommended treatments, VRd, VMP and Rd compared to dexamethasone, were 0.31 (95%CI: 0.16-0.59), 0.39 (95%CI: 0.20-0.75), and 0.44 (95%CI: 0.29-0.65), respectively. Selecting MPT as a reference treatment does not change the hierarchy of the treatments as the *P*-score values do not change if one considers a different reference treatment. Compared to MPT, only DaraVMP had a statistically lower HR for PFS (HR 0.41, 95%CI: 0.19-0.91; *P*\<0.05) (*Online Supplementary Appendix 6*).

![Results of the network meta-analysis in which dexamethasone was used as comparator. HR: hazard ratio; CI: confidence interval. For abbreviations for treatments, see [Figure 2](#f2-1041026){ref-type="fig"}.](1041026.fig3){#f3-1041026}

Scenario analysis network meta-analysis
---------------------------------------

In order to rule out that grouping of MPT and MPT-T would affect the outcome of the analysis, we performed a scenario in which we grouped IFM 01/01, IFM 99/06 and Sacchi *et al*. 2011, as MPT and GIMEMA, HOVON49, TMSG and NMSG as MPT-T. The MPT-T group was connected in the network to the MPT-T arm from the HOVON87 trial and the ECOG E1A06 trial. Overall, the results were comparable to the base case (*Online Supplementary Appendix 7*). We found similar results for MPT (HR 0.46, 95%CI: 0.30-0.71) and MPT-T (HR 0.47, 95% CI 0.30-0.73) compared to D.

The second scenario, based on the trials included by Weisel *et al*.,^[@b12-1041026]^ showed lower HRs for PFS for Rd compared to VMP, MPT and MP, but the 95%CI for VMP overlapped with Rd \[Rd *vs*. VMP: HR 0.73, 95%CI: 0.48-1.11 (*Online Supplementary Appendix 8*)\].

Results from the third scenario analysis (fixed effect model instead of random effects model) are presented in *Online Supplementary Appendix 9*. While the HRs from the fixed effect model are quite similar, the 95%CIs are smaller, as is typical for fixed effect models.

Discussion
==========

Current clinical decision making in MM is complicated by a lack of head-to-head comparisons of standards of care, an increasing number of treatment modalities, and rapidly evolving promising results of studies with novel regimens (among smaller subpopulations). In this treatment landscape, we believe the role of NMA will become increasingly important, although it cannot replace RCTs, and these will still represent the gold standard.

Firstly, NMAs are able to provide data where head-to-head comparisons are lacking.^[@b20-1041026],[@b24-1041026]^ For NTE NDMM, there have been no head-to-head comparisons between the current three standard of care regimens (i.e. VRd, VMP and Rd). Only VRd has been compared head-to-head with Rd, and there are no studies comparing VMP with VRd or Rd. With our NMA, we show that the HR of VRd was lower than VMP and Rd, and VRd also had the highest *P*-score. We present similar HRs and *P*-scores for VMP and Rd. However, we also show considerable overlap of the 95%CIs of VRd, Rd and VMP. Our NMA does not support the use of one over the other regimens, thus leaving three valuable options for clinical practice. The choice of therapy will be guided by the patient's characteristics. For example, a proteasome inhibitor (PI)-based regimen in high-risk cytogenetic disease, and a preference for lenalidomide without bortezomib in patients with neuropathy.^[@b31-1041026]--[@b34-1041026]^

According to the ranking based on their *P*-scores and comparative effectiveness estimates, DaraVMP and VMPT-VT were identified as the most effective treatments. Although there is one RCT already showing better PFS and OS^[@b28-1041026]^ for VMPT-VT when compared with VMP, we now add data showing comparable efficacy to DaraVMP, which is expected to become an important standard of care. This finding is important given the pronounced differences in global access to expensive treatment regimens. As all drugs in the VMPT-VT regimen will soon be available as generic compounds, this regimen is a valuable option in clinical practice as well. In addition, the pronounced efficacy of VMPT-VT highlights the use of maintenance therapy following PI-based induction regimens. In addition, in a non-head-to-head comparison with VMP, the study of the PETHEMA group showed that maintenance therapy did result in a substantially longer PFS.^[@b35-1041026]^ We now add further evidence for maintenance therapy with PIs by showing high efficacy of VMPT-VT as compared to VMP. This is important because the European Medicines Agency has still not approved maintenance therapy with bortezomib, given that no head-to-head comparisons of maintenance *versus* no maintenance therapy have been made.

Secondly, NMAs provide more solid and precise effectiveness estimates when head-to-head data from multiple RCTs are available.^[@b20-1041026],[@b24-1041026]^ Our network included several trials investigating MPT/MPT-T *versus* MP. Some of these trials showed superiority of MPT/MPT-T over MP,^[@b26-1041026],[@b27-1041026],[@b36-1041026]^ while other trials found no difference.^[@b37-1041026]--[@b40-1041026]^ NMA enables this evidence to be synthesized and, according to our analysis, MPT/MPT-T was superior over MP (HR 0.67, 95%CI: 0.55-0.81).

Thirdly, NMA calculates effectiveness estimates including direct and indirect evidence from RCTs providing additional evidence when head-to-head data are only available from one single RCT. Due to the rapid evolution of the treatment armamentarium, efficacy evidence is increasingly based on a single RCT, and this is often from only one institute or region in the world. There is increasing evidence of RCTs investigating a similar treatment comparison providing contradictory results^[@b41-1041026]^ and this may increase the interest in indirect evidence. Indirect evidence may confirm or alter the results from a single RCT, as we have shown for MPR-R compared to MPT. Although there was no statistically significant difference between MPR-R and MPT-T based on direct evidence from two RCTs, synthesizing direct and indirect evidence resulted in a statistically significant HR for MPR-R compared to MPT/MPT-T. Favorable indirect evidence for MPR-R compared to MPT-T was obtained through the comparison with MP. MPR-R compared more favorably to MP (according to the MM-15 HR MPR-R *vs*. MP 0.4) than MPT (HR MPT *vs*. MP 0.67 according to multiple trials). However, it should be noted that the direct evidence for MPR-R compared to MP was based on a single RCT while MPT/MPT-T *versus* MP was studied in seven RCTs, and therefore the evidence for the latter comparison is believed to be more solid.^[@b24-1041026],[@b41-1041026]^ Indirect evidence is not always available, for example, for the comparison between VRd and Rd there is only direct evidence from a single study.^[@b6-1041026]^ While a fixed effect NMA will produce similar results to the trial (HR 0.71, 95%CI: 0.57-0.9), a random effects NMA obtains larger 95%CIs (HR 0.71, 95%CI: 0.43-1.17), as it includes two levels of uncertainty: within and between study variances.^[@b17-1041026]^ Therefore, there is less likelihood of significant differences between treatments.

Two other NMAs are available for newly diagnosed NTE NDMM patients. Our results align with the results from Kuhr *et al*.^[@b11-1041026]^ in that VMP and MPT are more effective than MP. Our results also confirm the conclusion from Weisel *et al*.^[@b12-1041026]^ that Rd is more favorable than MP \[HR 0.63, 95%CI: 0.44-0.89 (*Online Supplementary Appendix 5*)\]. However, in contrast to their findings, we found that Rd and VMP have comparable effectiveness outcomes (i.e. small difference in HR for PFS compared to D but largely overlapping CIs). The primary analysis of Weisel *et al*. included a limited number of treatments (i.e. VMP, MP, MPT and Rd) and RCTs (i.e. VISTA, IFM01/01, IFM 99/06, Sacchi, FIRST) as Phase III trials not using dosing schemes in line with the summary of product characteristics (SmPC) were excluded. There are several arguments against this restriction. Firstly, although dosing schemes in line with the SmPC might be recommended in the selected trials by Weisel *et al*., it is debatable whether this ensures treatments are identical within a network, especially because of variation in clinical practice due to either physician's preference or patient-related factors such as age, co-morbidities and toxicities. For example, the trial of Sacchi *et al*. 2011 was grouped with MPT studies while maintenance was only provided in a limited number of centers. Furthermore, the administered and planned dose may differ, as, for example, illustrated by the HOVON87 in which relative dose intensity varied between 0.54-0.96.^[@b13-1041026]^ Since there is no evidence on the impact of dosing schemes, we believe that a more comprehensive network (e.g. our network, including 19 additional trials) provides more solid evidence. The reason Weisel *et al*.^[@b12-1041026]^ did not find an overlap between VMP and Rd in their sensitivity analyses including six and twelve additional studies, is most likely because they used a fixed effect model for their analysis. A random effects model, like that used in our analysis and by Kuhr *et al*.,^[@b11-1041026]^ is, however, more appropriate, as this model allows for the between study-heterogeneity in the additional studies.

One might argue that while our NMA provides additional evidence in different circumstances, we had to make assumptions in order to conduct the analysis, and that this introduces a level of uncertainty. Firstly, we grouped MPT and MPT-T studies together since we could not make an unambiguous distinction between them. For example, thalidomide was prescribed until disease progression in the HOVON49 and GIMEMA trial but prescribed "continuously" for up to a maximum of 12 months in the TMSG trial. In the NMSG trial, it was even recommended to continue thalidomide maintenance until second relapse. However, most investigators discontinued thalidomide at first relapse. Prescription of thalidomide was also not consistent within a trial.^[@b38-1041026]^ Sacchi *et al*.^[@b38-1041026]^ described that, although planned, maintenance was only provided to 18% of the patients and in a limited number of centers. Their results, however, showed that there was no difference in PFS between maintenance and no-maintenance approaches.^[@b42-1041026]^ Therefore, we believe that it is appropriate to combine these trials, as performed previously,^[@b11-1041026],[@b43-1041026]^ and the results of our sensitivity analysis confirm this assumption (see *Online Supplementary Appendix 7*).

Secondly, the validity of the outcomes of NMA depends on the comparability between studies. Our analysis focused on treatments for NTE NDMM patients studied in phase III RCTs. Although it is possible to include non-randomized evidence in NMA,^[@b45-1041026]^ and this could have provided additional information regarding effectiveness in clinical practice^[@b46-1041026]--[@b48-1041026]^ or treatments not analyzed in a phase III RCT (e.g. bortezomib-cyclophosphamide-dexamethasone, VCD49), we believe that limiting our analysis to the relative effectiveness of RCT evidence reduces the risk of bias and systematic errors.^[@b44-1041026]^ Further research to improve methodologies for conducting, evaluating and interpreting non-randomized evidence is recommended.^[@b44-1041026]^ We focused on NTE NDMM treatment to increase homogeneity between the patient populations in the study. We observed between-study heterogeneity comparable to the proportions previously reported by Kuhr *et al*.^[@b11-1041026]^ We allow for this heterogeneity by using a random effects instead of a fixed effect model. However, the consequence of this is larger 95%CIs.

A potential limitation of our search strategy is that we only included English language publications. To the best of our knowledge, this does not, however, lead to the exclusion of relevant studies or treatments. Furthermore, our NMA was limited to the intermediate outcome PFS and did not include other outcomes of interest such as OS, adverse events, quality of life, cost, and cost-effectiveness. While OS may even be the most important subject of investigation for patients and health care decision makers, we believe a comparison of OS for first-line therapies with the currently available data is prone to bias due to crossover, heterogenous and limited follow up (e.g. especially for DaraVMP: median OS was not reached at 16.5 months follow up), and different subsequent treatment lines.^[@b50-1041026],[@b51-1041026]^ In the context of increasing health care expenditures, cost-effectiveness is also another relevant and important outcome, and this remains a subject for further research. Several treatment options showed comparable effectiveness outcomes, but costs could very well differ due to drug prices, treatment duration, and route of administration. Our study facilitates cost-effectiveness research on first-line NTE treatments.

The treatment armamentarium is rapidly increasing and evolving for NTE NDMM patients, and NMAs will, therefore, become increasingly important. We illustrate the additional value and evidence that can be provided. NMAs support evidence-based decision making and may help optimize treatment and outcomes of NTE NDMM patients in clinical practice.
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